Victor Francisco
Primary Care · Lauderhill, FLNPI 1508260373
Payments from drug & device makers
Across 88 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$320
- Astellas Pharma US Inc$188
- Abiomed$183
- GSK$160
- Novartis$129
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$115
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,15495%
- Education$1235%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $320 |
| Astellas Pharma US Inc | 4 | $188 |
| Abiomed | 2 | $183 |
| GSK | 3 | $160 |
| Novartis | 7 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $115 |
| Johnson & Johnson | 5 | $102 |
| Heartflow, Inc. | 1 | $100 |
| Amgen(2 entities) | 5 | $99 |
| Lilly USA, LLC | 5 | $87 |
| Boehringer Ingelheim | 4 | $82 |
| Novo Nordisk | 4 | $80 |
| Bayer | 3 | $72 |
| Pfizer | 4 | $71 |
| Phadia US Inc. | 3 | $54 |
| Medtronic | 2 | $51 |
| Exact Sciences | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Hologic Sales And Service, LLC | 1 | $37 |
| Stryker | 1 | $36 |
| Merck | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Shield Therapeutics Inc | 1 | $27 |
| Abbott | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$141
- TRELEGY ELLIPTA$125
How this compares
$2,277 in reported general payments places this provider in the 85th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 134 | $146,590 |
| RybelsusSemaglutide | 55 | $105,751 |
| FarxigaDapagliflozin Propanediol | 127 | $99,492 |
| EliquisApixaban | 88 | $93,350 |
| OzempicSemaglutide | 65 | $72,826 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $66,770 |
| TradjentaLinagliptin | 52 | $48,269 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $44,373 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $40,816 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $38,397 |
| JanuviaSitagliptin Phosphate | 42 | $34,904 |
| EntrestoSacubitril/Valsartan | 25 | $33,896 |
| XareltoRivaroxaban | 26 | $27,396 |
| TrulicityDulaglutide | 24 | $26,135 |
| MyrbetriqMirabegron | 30 | $23,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $82 | $194,859186 claims |
| Novo NordiskRybelsus, Ozempic | $80 | $178,577120 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $320 | $117,311166 claims |
| PfizerEliquis | $71 | $93,35088 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $160 | $67,236110 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $87 | $47,52744 claims |
| MerckJanuvia | $35 | $34,90442 claims |
| NovartisEntresto | $129 | $33,89625 claims |
| Johnson & JohnsonXarelto | $102 | $27,39626 claims |
| Astellas Pharma US IncMyrbetriq | $188 | $23,24030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 725 primary care providers in Florida.
Other primary care in Lauderhill
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Maria Rodriguez ReyesHialeah$31K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.